Achieving Optimal Outcomes in Patients with Narcolepsy: Aligning Treatment Goals with PatientsPremiere Date: Monday, June 13, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, June 13, 2023
|Richard K. Bogan, MD, FCCP, FAASM (Moderator)
President, Bogan Sleep Consultants, LLC
Associate Clinical Professor
University of South Carolina School of Medicine
Associate Clinical Professor
Medical University of South Carolina
|Julie Flygare, JD
President & CEO, Project Sleep
Author, Wide Awake and Dreaming: A Memoir of Narcolepsy
Los Angeles, CA
|Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology
|Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM
Professor Emerita of Biobehavioral Nursing Science
College of Nursing University of Illinois Chicago
Professor Emerita of Nursing
University of Pennsylvania
Narcolepsy is a devastating, neurological condition characterized by excessive daytime sleepiness (EDS), the most common presenting symptom, as well as cataplexy, hypnagogic hallucinations, and sleep paralysis. Though recent practice guidelines have been released, these guidelines do not include recent U.S. Food and Drug Administration (FDA) approvals with strategies to lower sodium, which may be an ideal treatment option in patients with cardiovascular (CV) comorbidities or risk factors. As patients with narcolepsy often experience residual EDS despite traditional treatment, it is imperative that health care professionals (HCPs) possess the knowledge to identify EDS and skills to integrate effective novel therapies to achieve sustained benefits to optimize patient outcomes.
Join Drs. Bogan, Thorpy, and Weaver for an OnDemand symposium as they discuss evidence-based strategies to reduce EDS and cataplexy, among other symptoms, and restore quality of life and functioning in patients with narcolepsy.
At the end of this CE activity, participants should be able to:
- Explain the patient's journey with narcolepsy, including the extensive impact of work, psychosocial, and daily functioning to overall health.
- Analyze the practice implications using evidence-based screening tools and diagnostic criteria to accelerate the early, accurate diagnosis of narcolepsy.
- Integrate strategies to mitigate CV risk associated with narcolepsy in treatment decision-making.
- Implement evidence-based strategies for the initiation and/or switching of therapies to improve and sustain patient QoL and psychosocial and work functioning.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep medicine, psychiatry, neurology, pulmonology and/or primary care
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Bogan reports the following financial relationships:
Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Ms. Flygare reports the following financial relationships:
Consultant: Orexia Therapeutics and Takeda Pharmaceutical Company Limited
Dr. Thorpy reports the following financial relationships:
Advisory Board and Consultant: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma
Dr. Weaver reports the following financial relationships:
Advisory Board: Idorsia Pharmaceuticals Alliance for Sleep
Consultant: Bayer and Eli Lilly and Company
Other Financial Support: Axsome Therapeutics, Inc.; Bayer AG; Clinical Outcomes Solutions; Cook Medical; Eli Lilly and Company; Functional Outcomes of Sleep Questionnaire (FOSQ); Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; LivaNova PLC; Nyxoah; Philips Respironics; ResMed; ResMed Germany; RWS; Signant Health; Signifier Medical Technologies; Stratevi; Valis Biosciences Inc.; and Verily Life Sciences
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).